Microscopic polyangiitis

Microscopic polyangiitis
ICD-10	M31.7
DiseasesDB	8193

WikiDoc Resources for Microscopic polyangiitis
Articles
Most recent articles on Microscopic polyangiitis Most cited articles on Microscopic polyangiitis Review articles on Microscopic polyangiitis Articles on Microscopic polyangiitis in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Microscopic polyangiitis Images of Microscopic polyangiitis Photos of Microscopic polyangiitis Podcasts & MP3s on Microscopic polyangiitis Videos on Microscopic polyangiitis
Evidence Based Medicine
Cochrane Collaboration on Microscopic polyangiitis Bandolier on Microscopic polyangiitis TRIP on Microscopic polyangiitis
Clinical Trials
Ongoing Trials on Microscopic polyangiitis at Clinical Trials.gov Trial results on Microscopic polyangiitis Clinical Trials on Microscopic polyangiitis at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Microscopic polyangiitis NICE Guidance on Microscopic polyangiitis NHS PRODIGY Guidance FDA on Microscopic polyangiitis CDC on Microscopic polyangiitis
Books
Books on Microscopic polyangiitis
News
Microscopic polyangiitis in the news Be alerted to news on Microscopic polyangiitis News trends on Microscopic polyangiitis
Commentary
Blogs on Microscopic polyangiitis
Definitions
Definitions of Microscopic polyangiitis
Patient Resources / Community
Patient resources on Microscopic polyangiitis Discussion groups on Microscopic polyangiitis Patient Handouts on Microscopic polyangiitis Directions to Hospitals Treating Microscopic polyangiitis Risk calculators and risk factors for Microscopic polyangiitis
Healthcare Provider Resources
Symptoms of Microscopic polyangiitis Causes & Risk Factors for Microscopic polyangiitis Diagnostic studies for Microscopic polyangiitis Treatment of Microscopic polyangiitis
Continuing Medical Education (CME)
CME Programs on Microscopic polyangiitis
International
Microscopic polyangiitis en Espanol Microscopic polyangiitis en Francais
Business
Microscopic polyangiitis in the Marketplace Patents on Microscopic polyangiitis
Experimental / Informatics
List of terms related to Microscopic polyangiitis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]

Synonyms and keywords: MPA

Overview

Microscopic polyangiitis (MPA) is an ill-defined autoimmune disease characterized by pauci-immune, necrotizing, small-vessel vasculitis without clinical or pathological evidence of necrotizing granulomatous inflammation. Because many different organ systems may be involved, a wide range of symptoms are possible in MPA.

Historical Perspective

• [Disease name] was first discovered by [scientist name], a [nationality + occupation], in [year] during/following [event].
• In [year], [gene] mutations were first identified in the pathogenesis of [disease name].
• In [year], the first [discovery] was developed by [scientist] to treat/diagnose [disease name].

Classification

• [Disease name] may be classified according to [classification method] into [number] subtypes/groups:

• [group1]
• [group2]
• [group3]

• Other variants of [disease name] include [disease subtype 1], [disease subtype 2], and [disease subtype 3].

Pathophysiology

• The pathogenesis of [disease name] is characterized by [feature1], [feature2], and [feature3].
• The [gene name] gene/Mutation in [gene name] has been associated with the development of [disease name], involving the [molecular pathway] pathway.
• On gross pathology, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].
• On microscopic histopathological analysis, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].

Cause

This condition, the clinical picture of which may include many features of systemic lupus erythematosis, has been reported to have been caused by antibiotics and also by certain infections, though, as with many autoimmune diseases, the causes remain to a large extent unknown.

Differentiating [disease name] from other Diseases

• [Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as:

• [Differential dx1]
• [Differential dx2]
• [Differential dx3]

Epidemiology and Demographics

• The prevalence of [disease name] is approximately [number or range] per 100,000 individuals worldwide.
• In [year], the incidence of [disease name] was estimated to be [number or range] cases per 100,000 individuals in [location].

Age

• Patients of all age groups may develop [disease name].

• [Disease name] is more commonly observed among patients aged [age range] years old.
• [Disease name] is more commonly observed among [elderly patients/young patients/children].

Gender

• [Disease name] affects men and women equally.

• [Gender 1] are more commonly affected with [disease name] than [gender 2].
• The [gender 1] to [Gender 2] ratio is approximately [number > 1] to 1.

Race

• There is no racial predilection for [disease name].

• [Disease name] usually affects individuals of the [race 1] race.
• [Race 2] individuals are less likely to develop [disease name].

Risk Factors

• Common risk factors in the development of [disease name] are [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4].

Natural History, Complications and Prognosis

• The majority of patients with [disease name] remain asymptomatic for [duration/years].
• Early clinical features include [manifestation 1], [manifestation 2], and [manifestation 3].
• If left untreated, [#%] of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
• Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
• Prognosis is generally [excellent/good/poor], and the [1/5/10­year mortality/survival rate] of patients with [disease name] is approximately [#%].

Diagnosis

Laboratory findings

Laboratory tests show an increased sedimentation rate, reduced red blood count, antineutrophil cytoplasmic antibodies (p-ANCA) directed against [MPO(a constituent of neutrophil granules), and protein and red blood cells in the urine.

The test for anti-glomerular basement membrane antibody (GBM), which is positive in Goodpasture's syndrome, is negative.

Imaging Findings

• There are no [imaging study] findings associated with [disease name].

• [Imaging study 1] is the imaging modality of choice for [disease name].
• On [imaging study 1], [disease name] is characterized by [finding 1], [finding 2], and [finding 3].
• [Imaging study 2] may demonstrate [finding 1], [finding 2], and [finding 3].

Other Diagnostic Studies

• [Disease name] may also be diagnosed using [diagnostic study name].
• Findings on [diagnostic study name] include [finding 1], [finding 2], and [finding 3].

Treatment

Medical Therapy

The customary treatment involves long term dosage of prednisone, alternated or combined with cytotoxic drugs, such as cyclophosphamide or azathioprine. Plasmapheresis may also be indicated in the acute setting to remove ANCA antibodies.

Related Chapters

• ANCA-associated vasculitides
• Polyarteritis nodosa

Template:WikiDoc Sources